AlphaRx And Gaia BioPharma Report Positive Efficacy Results In A Pre-Clinical Trial Of GAI-122 Injectable Nano-emulsion For Post-operative Delirium

AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia. Delirium is a common mental disorder with serious adverse outcomes in post-operative hospitalized patients.

More: continued here

Filed under: Clinical Trials on June 30th, 2009